Introducing OmniSeq INSIGHTSM

OmniSeq INSIGHTSM is a comprehensive, tissue-based, next generation sequencing genomic profiling device clinically and analytically validated for all solid tumors. The test is designed to detect genomic variants, signatures, and immune gene expression to provide physicians with clinically actionable evidence to inform therapeutic treatment decisions and identify potential clinical trial options based on an individual genomic profile of each patient.  Results are intended for use by qualified health care professionals in accordance with professional guidelines in oncology for management of patients with solid neoplasms, and is not conclusive or prescriptive for labeled use of any specific therapeutic product.

Cancer Type
All Solid Tumors

Specimen Type
FFPE

Specimen Requirements
Preferred: FFPE Block
Alternate: 20 unstained slides

Typical Turnaround Time
10 days or less from receipt of specimen

Expanded Insight = Increased Options

Marker-Driven FDA Approved Therapy Associations

Markers with NCCN Therapeutic Guidance Evidence

Markers with Clinical Trial Associations

Industry-guided content for a comprehensive view of cancer-related fusion genes, detecting common and novel fusions.

Detect Fusions Missed By DNA-seq

Effectively Match Patients to the Right Trial
MOLECULAR + IMMUNE PROFILING = MORE PATIENT OPTIONS

PROFILING THE ACTIONABLE CANCER GENOME

Comprehensive Trial Matching Across the Actionable Cancer Genome for Solid Tumors

Genes

Trials

Expertly Curated Clinical Trial Matching Assessing Biomarker-Based Eligibility Criteria, Multi-Arm Study Designs and Treatment Context Assertions

PROFILING THE TUMOR MICROENVIRONMENT

Increase Clinical Trial Options by Targeting Biomarkers Involved in the Adaptive Immune System

Genes

Trials

Understanding the Anti-Cancer Immune Response is Critical to Adapt Therapies to the Cancer Phenotype.

OmniSeq Delivers the Only Test Matching Trials to Tumor-Immune Mechanisms and Low-Expressing Genes Involved in Inflammatory Signaling 

Trust a test provider ISO13485 CERTIFIED to design, develop and deliver DNA and RNA testing for the medical management and identification of genomic and immune biomarkers in oncology.